Pryor Cashman represented Marina Biotech, Inc. (NASDAQ: MRNA) in a firm commitment underwritten public offering of approximately $5.1 million of common stock and warrants, which closed on February 15, 2011. Roth Capital Partners served as the sole manager for the offering.

Marina Biotech is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference.

Marina Biotech anticipates using the proceeds from this offering for general corporate purposes (including working capital and operational purposes) and toward the clinical development of CEQ508, which is currently in a Phase 1b/2a clinical trial for the treatment of Familial Adenomatous Polyposis.

Representing Marina Biotech on the transaction were Pryor Cashman Partner Larry Remmel, Counsel Michael T. Campoli and associate Robert C. Lamonica.